Hengrui Pharma(SH:600276) Xin Lang Cai Jing·2025-09-10 03:07Core Viewpoint - Heng Rui Medicine's stock price has shown significant growth this year, with a 61.40% increase, indicating strong market performance and investor interest [2]. Company Overview - Jiangsu Heng Rui Medicine Co., Ltd. is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology and related fields [2]. - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, with applications across various diseases including autoimmune, metabolic, cardiovascular, infectious, respiratory, hematological, pain management, neurological, ophthalmic, and renal diseases [2]. - The revenue composition is as follows: oncology 52.12%, neuroscience 15.33%, others 10.63%, contrast agents 9.82%, metabolic and cardiovascular 6.25%, others 3.07%, and immunology and respiratory 2.78% [2]. Financial Performance - For the first half of 2025, Heng Rui Medicine reported a revenue of 15.76 billion yuan, a year-on-year increase of 15.88%, and a net profit attributable to shareholders of 4.45 billion yuan, up 29.67% year-on-year [3]. - The company has distributed a total of 9.30 billion yuan in dividends since its A-share listing, with 3.57 billion yuan distributed in the last three years [4]. Shareholder Information - As of June 30, 2025, the number of shareholders is 364,700, a decrease of 11.27% from the previous period, with an average of 17,493 circulating shares per person, an increase of 12.70% [3]. - Major shareholders include Hong Kong Central Clearing Limited, which holds 535 million shares, an increase of 143 million shares from the previous period [4].